| scholarly article | Q13442814 |
| P2093 | author name string | Rubin M | |
| Kelly P | |||
| Lee J | |||
| Walsh TJ | |||
| Pizzo PA | |||
| Rinaldi MG | |||
| Lecciones J | |||
| McGough DA | |||
| Melcher GP | |||
| Callender D | |||
| P2860 | cites work | Emergence of a new opportunistic pathogen, Candida lusitaniae | Q37168423 |
| Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection | Q37280206 | ||
| Trichosporonosis. | Q38610546 | ||
| Diagnosis and successful treatment of fusariosis in the compromised host | Q39535499 | ||
| Trichosporonosis in patients with neoplastic disease | Q39737308 | ||
| Trichosporon beigelii infection: a review | Q39753103 | ||
| Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. | Q40220304 | ||
| Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function | Q40354286 | ||
| Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis | Q40647196 | ||
| Favorable outcome of invasive aspergillosis in patients with acute leukemia | Q40791575 | ||
| Colonization and infection with Trichosporon species in the immunosuppressed host | Q44338826 | ||
| Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. | Q54504401 | ||
| Amphotericin B-resistant yeast infection in severely immunocompromised patients | Q68136440 | ||
| Disseminated infection with Trichosporon beigelii | Q68779471 | ||
| Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii | Q70047840 | ||
| Demonstration, by immunoelectronmicroscopy, of a cell wall antigen in Trichosporon beigelii that cross-reacts with Cryptococcus neoformans capsular polysaccharide | Q70215366 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Trichosporon beigelii | Q7841012 |
| amphotericin B | Q412223 | ||
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 1616-1622 | |
| P577 | publication date | 1990-07-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Trichosporon beigelii, an emerging pathogen resistant to amphotericin B | |
| P478 | volume | 28 |
| Q38265809 | A Rare Case of Nosocomial Urinary Tract Infection due to Trichosporon asahii |
| Q41987567 | A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats |
| Q36949656 | A novel murine model of disseminated trichosporonosis |
| Q35112069 | Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections |
| Q34294886 | Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. |
| Q38111293 | Amphotericin B formulations: a comparative review of efficacy and toxicity |
| Q34400044 | Antifungal agents: chemotherapeutic targets and immunologic strategies |
| Q35688450 | Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy |
| Q36882122 | Antifungal chemotherapy — Are we winning? |
| Q34594076 | Antifungal drug resistance of pathogenic fungi. |
| Q40878512 | Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches |
| Q43664354 | Antifungal susceptibility of emerging yeast pathogens |
| Q40795131 | Antifungal susceptibility testing |
| Q33975757 | Antifungal susceptibility testing: practical aspects and current challenges |
| Q33538696 | Antifungals: mechanism of action and resistance, established and novel drugs |
| Q37666705 | Antifungals: need to search for a new molecular target |
| Q64931517 | Catheter associated urinary tract infections due to Trichosporon asahii. |
| Q41108726 | Catheter-related complications of cancer therapy |
| Q93338789 | Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections |
| Q33716130 | Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism |
| Q41740968 | Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development |
| Q34993877 | Clinical relevance of mechanisms of antifungal drug resistance in yeasts |
| Q33721804 | Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. |
| Q35822118 | Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis |
| Q44044248 | Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates |
| Q26998573 | Current knowledge of Trichosporon spp. and Trichosporonosis |
| Q49204068 | Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species |
| Q90044837 | Disseminated Trichosporon asahii infection in a combined liver-kidney transplant recipient successfully treated with voriconazole |
| Q55431196 | Disseminated Trichosporon beigelii infection in an immunosuppressed child. |
| Q40683456 | Disseminated Trichosporon beigelii infection in patients with malignant diseases: immunohistochemical study and review |
| Q37128029 | Disseminated hyalohyphomycosis caused by a novel human pathogen, Fusarium napiforme |
| Q24649737 | Disseminated trichosporonosis caused by Trichosporon loubieri |
| Q41081332 | Disseminated trichosporonosis in a neutropenic murine model |
| Q67884468 | Disseminated trichosporonosis: Meeting the challenge |
| Q35553643 | Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis. |
| Q73348103 | Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes against Trichosporon asahii |
| Q28379470 | Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis |
| Q41009125 | Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis |
| Q42153472 | Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. |
| Q33770019 | Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits |
| Q87649547 | Emerging Trichosporon asahii in elderly patients: epidemiological and molecular analysis by the DiversiLab system |
| Q34294875 | Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century |
| Q35988869 | Emerging pan-resistance in Trichosporon species: a case report |
| Q36241645 | Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014. |
| Q37327072 | Epidemiology of invasive fungal infection |
| Q35372424 | Epidemiology of nosocomial fungal infections |
| Q33689568 | Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models |
| Q37021358 | Fatal disseminated Trichosporon asahii infection in a child with acute lymphoblastic leukemia |
| Q48062325 | Fatal invasive trichosporonosis due toTrichosporon loubieriin a patient with T-lymphoblastic lymphoma |
| Q44809992 | Fatal trichosporonosis is not related to tolerance to amphotericin B |
| Q35038473 | Fungal infections in nontransplant patients with hematologic malignancies |
| Q36841586 | Fungal infections in primary immunodeficiencies |
| Q34404601 | Fungal infections: a growing threat |
| Q33961800 | Fungal resistance |
| Q37159199 | Genetic diversity and antifungal susceptibility testing of Trichosporon asahii isolated of Intensive Care Units patients |
| Q42110115 | Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii |
| Q28550113 | In Vitro Interactions between Non-Steroidal Anti-Inflammatory Drugs and Antifungal Agents against Planktonic and Biofilm Forms of Trichosporon asahii |
| Q42727587 | In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis. |
| Q33979873 | In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum |
| Q33961573 | In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. |
| Q34317476 | In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature |
| Q34106411 | In vitro antifungal susceptibilities of Trichosporon species. |
| Q40968349 | In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. |
| Q77491810 | In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species |
| Q28355507 | In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi |
| Q82866864 | In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii |
| Q53925361 | Infections in patients with aplastic anemia: experience at a tertiary care cancer center. |
| Q34348047 | Infectious morbidity in critically ill patients with cancer |
| Q93335314 | Invasive Infections Due to Trichosporon: Species Distribution, Genotyping, and Antifungal Susceptibilities from a Multicenter Study in China |
| Q28071847 | Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen |
| Q28243864 | Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature |
| Q33594520 | Invasive yeast infections other than Candida spp. in acute leukaemia |
| Q40774494 | Management of immunocompromised patients with evidence of an invasive mycosis. |
| Q44380989 | Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species |
| Q24550785 | Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units |
| Q30452880 | New and emerging yeast pathogens |
| Q33959283 | PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis. |
| Q40968227 | Patterns of amphotericin B killing kinetics against seven Candida species. |
| Q27025299 | Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications |
| Q46478249 | Pneumonia caused by Trichosporon pullulans in an autologous peripheral blood stem cell transplant recipient: possible misidentification |
| Q64070466 | Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B |
| Q40111798 | Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q37373824 | Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. |
| Q37377752 | Recent approaches to antifungal therapy for invasive mycoses. |
| Q41108756 | Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients |
| Q46345548 | Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes |
| Q79340352 | Resistance to amphotericin B: emerging clinical and microbiological patterns |
| Q40531623 | Resistance to antifungal agents |
| Q40395756 | Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor |
| Q34077156 | Susceptibility patterns and molecular identification of Trichosporon species |
| Q36528018 | Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome |
| Q40960931 | Targeting fungi: a challenge |
| Q34195380 | Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study |
| Q36442845 | The child with cancer and infection. II. Nonbacterial infections |
| Q41121097 | The superficial mycoses |
| Q37800610 | The value of amphotericin B in the treatment of invasive fungal infections |
| Q42918778 | Trichosporon Surgical Wound Infection in a Renal Allograft Recipient Successfully Treated With Voriconazole |
| Q48299565 | Trichosporon asahii septic thrombophlebitis following lower extremity amputation in an immunocompetent host. |
| Q40872953 | Trichosporon asahii urinary tract infection in immunocompetent patients |
| Q40683035 | Trichosporon beigelii Pneumonia in Patients With Hematologic Malignancies |
| Q33919410 | Trichosporon beigelii infection: experience in a regional burn center |
| Q33879950 | Trichosporon beigelii: a life-threatening pathogen in immunocompromised hosts |
| Q34748873 | Trichosporon loubieri infection in a patient with adult polycystic kidney disease |
| Q34995831 | Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis |
| Q35999226 | Two Case Presentations Infected by Trichosporon asahii and Treated with Voriconazole Successfully |
| Q37196298 | Update on the genus Trichosporon |
| Q54695894 | [Medical relevance of the identification of human pathogenic fungi to species level]. |
Search more.